Targeting SMAD4L535fs in LNCaP prostate cancer cells: Implications for therapy resistance and sensitivity (AACR 2025) - Mar 26, 2025 - Abstract #6798; Pres time: Apr 30, 2025; 09:00 AM - 12:00 PM; Location: Section 18; Poster Board No: 10; "SMAD4L535fs enhances the proliferation and chemoresistance of LNCaP prostate cancer cells, providing insight into potential therapeutic targets for overcoming drug resistance.Further studies are required to elucidate the molecular mechanisms underlying SMAD4L535fs-mediated ferroptosis resistance."
Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ANXA5 • SMAD4 • TGFB1
|
|
Chizhe Yi; Cindy Sin Ting Chow; Stephen Kwok Wing Tsui
|